[go: up one dir, main page]

WO2009034708A1 - 細胞増殖方法ならびに組織の修復および再生のための医薬 - Google Patents

細胞増殖方法ならびに組織の修復および再生のための医薬 Download PDF

Info

Publication number
WO2009034708A1
WO2009034708A1 PCT/JP2008/002503 JP2008002503W WO2009034708A1 WO 2009034708 A1 WO2009034708 A1 WO 2009034708A1 JP 2008002503 W JP2008002503 W JP 2008002503W WO 2009034708 A1 WO2009034708 A1 WO 2009034708A1
Authority
WO
WIPO (PCT)
Prior art keywords
heparin
regeneration
repair
tissue
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/002503
Other languages
English (en)
French (fr)
Inventor
Osamu Honmou
Kiyohiro Houkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sapporo Medical University
Original Assignee
Sapporo Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2007235436A external-priority patent/JP2009065854A/ja
Priority claimed from JP2007236499A external-priority patent/JP2009065884A/ja
Priority claimed from JP2007278083A external-priority patent/JP2009100719A/ja
Priority claimed from JP2007278049A external-priority patent/JP2009107929A/ja
Priority to CN2008801065843A priority Critical patent/CN101802174B/zh
Priority to DK08830989.3T priority patent/DK2194121T3/en
Priority to EP08830989.3A priority patent/EP2194121B1/en
Priority to ES08830989.3T priority patent/ES2611021T3/es
Priority to KR1020177027585A priority patent/KR102087366B1/ko
Priority to EP16182980.9A priority patent/EP3117828B1/en
Application filed by Sapporo Medical University filed Critical Sapporo Medical University
Priority to US12/677,610 priority patent/US9700582B2/en
Priority to CA2699236A priority patent/CA2699236C/en
Priority to JP2009532060A priority patent/JP4936341B2/ja
Priority to PL16182980T priority patent/PL3117828T3/pl
Priority to KR1020157036694A priority patent/KR20160005140A/ko
Priority to AU2008298816A priority patent/AU2008298816B2/en
Publication of WO2009034708A1 publication Critical patent/WO2009034708A1/ja
Anticipated expiration legal-status Critical
Priority to US15/617,571 priority patent/US10328102B2/en
Priority to US16/404,671 priority patent/US11426432B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C12N5/068—Stem cells; Progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C12N2500/62—DMSO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/91—Heparin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)

Abstract

　本発明は、生体の組織の修復・再生のための安全かつ有効な医薬を提供するために、生体から採取された細胞を、生体外で迅速かつ大量に増殖させる方法に関する。すなわち、本発明は、生体から採取された試料中の細胞を、培地中で培養して増殖させる方法であって、好ましくは血清癌マーカーおよび／または感染因子について陰性であることをあらかじめ検査した、同種血清を含む培地において、採取された試料に添加される抗凝固剤（例えば、ヘパリンもしくはヘパリン誘導体またはこれらの塩など）の量を該試料の容積に対して５Ｕ／ｍＬ未満とするか、または培養を開始する際の培地中の抗凝固剤の量を０．５Ｕ／ｍＬ未満とすることを特徴とする方法とその利用に関する。
PCT/JP2008/002503 2007-09-11 2008-09-10 細胞増殖方法ならびに組織の修復および再生のための医薬 Ceased WO2009034708A1 (ja)

Priority Applications (14)

Application Number Priority Date Filing Date Title
JP2009532060A JP4936341B2 (ja) 2007-09-11 2008-09-10 細胞増殖方法ならびに組織の修復および再生のための医薬
PL16182980T PL3117828T3 (pl) 2007-09-11 2008-09-10 Sposób namnażania komórek i środek farmaceutyczny do naprawy i regeneracji tkanek
DK08830989.3T DK2194121T3 (en) 2007-09-11 2008-09-10 CELL GROWTH PROCESS AND PHARMACEUTICAL COMPOSITION FOR tissue repair and regeneration
AU2008298816A AU2008298816B2 (en) 2007-09-11 2008-09-10 Cell growth method and pharmaceutical preparation for tissue repair and regeneration
KR1020157036694A KR20160005140A (ko) 2007-09-11 2008-09-10 조직 복구 및 재생을 위한 세포 증식 방법 및 약제학적 제제
EP08830989.3A EP2194121B1 (en) 2007-09-11 2008-09-10 Cell growth method and pharmaceutical preparation for tissue repair and regeneration
ES08830989.3T ES2611021T3 (es) 2007-09-11 2008-09-10 Método de crecimiento celular y preparación farmacéutica para reparación y regeneración de tejido
KR1020177027585A KR102087366B1 (ko) 2007-09-11 2008-09-10 조직 복구 및 재생을 위한 세포 증식 방법 및 약제학적 제제
EP16182980.9A EP3117828B1 (en) 2007-09-11 2008-09-10 Cell proliferation method, and pharmaceutical agent for repair and regeneration of tissue
CN2008801065843A CN101802174B (zh) 2007-09-11 2008-09-10 细胞增殖方法以及用于组织修复及再生的药物
US12/677,610 US9700582B2 (en) 2007-09-11 2008-09-10 Cell growth method and pharmaceutical preparation for tissue repair and regeneration
CA2699236A CA2699236C (en) 2007-09-11 2008-09-10 Cell growth method and pharmaceutical preparation for tissue repair and regeneration
US15/617,571 US10328102B2 (en) 2007-09-11 2017-06-08 Cell growth method and pharmaceutical preparation for tissue repair and regeneration
US16/404,671 US11426432B2 (en) 2007-09-11 2019-05-06 Cell growth method and pharmaceutical preparation for tissue repair and regeneration

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP2007235436A JP2009065854A (ja) 2007-09-11 2007-09-11 細胞増殖方法ならびに組織の修復および再生のための医薬
JP2007-235436 2007-09-11
JP2007236499A JP2009065884A (ja) 2007-09-12 2007-09-12 細胞増殖方法ならびに組織の修復および再生のための医薬
JP2007-236499 2007-09-12
JP2007-267211 2007-10-12
JP2007267211 2007-10-12
JP2007-278049 2007-10-25
JP2007-278083 2007-10-25
JP2007278049A JP2009107929A (ja) 2007-10-12 2007-10-25 損傷部位の修復を幇助する非経口全身投与剤
JP2007278083A JP2009100719A (ja) 2007-10-25 2007-10-25 改善された増殖能を有する細胞およびその評価方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/677,610 A-371-Of-International US9700582B2 (en) 2007-09-11 2008-09-10 Cell growth method and pharmaceutical preparation for tissue repair and regeneration
US15/617,571 Division US10328102B2 (en) 2007-09-11 2017-06-08 Cell growth method and pharmaceutical preparation for tissue repair and regeneration

Publications (1)

Publication Number Publication Date
WO2009034708A1 true WO2009034708A1 (ja) 2009-03-19

Family

ID=42113874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/002503 Ceased WO2009034708A1 (ja) 2007-09-11 2008-09-10 細胞増殖方法ならびに組織の修復および再生のための医薬

Country Status (12)

Country Link
US (3) US9700582B2 (ja)
EP (2) EP3117828B1 (ja)
JP (1) JP4936341B2 (ja)
KR (3) KR102087366B1 (ja)
CN (1) CN101802174B (ja)
AU (1) AU2008298816B2 (ja)
CA (1) CA2699236C (ja)
DK (2) DK2194121T3 (ja)
ES (2) ES2776408T3 (ja)
PL (2) PL3117828T3 (ja)
PT (2) PT3117828T (ja)
WO (1) WO2009034708A1 (ja)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018040A1 (ja) 2010-08-03 2012-02-09 北海道公立大学法人札幌医科大学 自己血清添加骨髄細胞培養システム、自己血清添加骨髄細胞培養方法および自己血清添加培養骨髄細胞を有効成分とする医薬組成物の製造方法
JP2016506954A (ja) * 2013-02-06 2016-03-07 Ｎｃメディカルリサーチ株式会社 神経変性の治療のための細胞療法
JP2017132744A (ja) * 2016-01-29 2017-08-03 学校法人東京女子医科大学 腎臓病進行抑制細胞シート組成物、その製造方法、及び、それを用いた腎臓病進行抑制方法
JP2017145259A (ja) * 2017-06-01 2017-08-24 Ｎｃメディカルリサーチ株式会社 神経変性の治療のための細胞療法
WO2018034023A1 (ja) * 2016-08-18 2018-02-22 北海道公立大学法人札幌医科大学 寿命延長剤
WO2018034314A1 (ja) * 2016-08-18 2018-02-22 北海道公立大学法人札幌医科大学 間葉系幹細胞活性化剤
WO2018043596A1 (ja) 2016-08-30 2018-03-08 国立大学法人 新潟大学 細胞製剤および細胞製剤の製造方法
WO2019093481A1 (ja) 2017-11-09 2019-05-16 北海道公立大学法人札幌医科大学 組織再生用医薬及びその製造方法
WO2019208688A1 (ja) * 2018-04-25 2019-10-31 北海道公立大学法人札幌医科大学 生体移植用細胞シート及びその製造方法
WO2020162580A1 (ja) 2019-02-07 2020-08-13 北海道公立大学法人 札幌医科大学 ステント内再狭窄の予防のための医薬組成物
JPWO2020184729A1 (ja) * 2019-03-14 2020-09-17
WO2021132662A1 (ja) * 2019-12-27 2021-07-01 北海道公立大学法人 札幌医科大学 哺乳動物細胞を培養するための血清の製造方法
WO2022049977A1 (ja) * 2020-09-03 2022-03-10 株式会社ツーセル 中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法
KR20220166875A (ko) 2016-04-28 2022-12-19 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 시냅스 형성제
JP2023035950A (ja) * 2021-08-31 2023-03-13 約書亞健康事業股▲ふん▼有限公司 ヘルニア嚢から間葉系幹細胞を単離精製する方法、及び組織修復するためのヘルニア嚢由来の間葉系幹細胞の使用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3117828T3 (pl) * 2007-09-11 2020-05-18 Sapporo Medical University Sposób namnażania komórek i środek farmaceutyczny do naprawy i regeneracji tkanek
US10016458B2 (en) 2012-04-16 2018-07-10 Baystate Health, Inc. p53 silenced endothelial progenitor cells for diabetes
US20160199414A1 (en) * 2013-09-05 2016-07-14 The Regents Of The University Of California Use of mesenchymal stem cells for the treatment of oral inflammation
US12171786B2 (en) 2015-10-05 2024-12-24 The Regents Of The University Of California Use of mesenchymal stem cells for the treatment of inflammation
CN105566460B (zh) * 2016-01-19 2018-11-23 南通大学 抑制肿瘤细胞增殖的多肽类似物和对应的编码cDNA及应用
CN106153919B (zh) * 2016-06-16 2018-06-29 汕头大学医学院 CD105，esVEGR2和MYC三蛋白联合预测食管鳞癌患者预后试剂盒
WO2018073615A1 (en) 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
CN109517789B (zh) * 2017-09-19 2022-05-27 北京大学 Ghrelin活性剂用于诱导干细胞向软骨细胞分化
CN108535479B (zh) * 2018-04-04 2019-04-19 首都医科大学附属北京地坛医院 sCD163检测试剂在梅毒检测中的应用及包括该试剂的试剂盒
CN110870917B (zh) * 2018-09-03 2022-03-15 上海市第一人民医院 Ews或其上调剂在制备治疗糖尿病及防治糖尿病个体肿瘤发生的药物中的应用
US12465878B2 (en) 2019-06-20 2025-11-11 Amniotics Ab Apparatus for filtering amniotic fluid
CN114765957B (zh) 2019-10-18 2025-09-12 Amniotics公司 从羊水中获得羊膜间充质干细胞的方法和设备及其来源的细胞
CN112899223A (zh) * 2019-12-04 2021-06-04 陕西光子动力航天科技有限公司 宫血干细胞制备方法
WO2021201029A1 (ja) 2020-03-31 2021-10-07 Ｃｅｌｌ Ｅｘｏｓｏｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 細胞の保存方法
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
CN112826920A (zh) * 2021-01-23 2021-05-25 中国人民解放军陆军军医大学 Id1/id3在诱导成纤维细胞重编程为施万细胞促进神经再生的应用
CN113652491A (zh) * 2021-02-02 2021-11-16 暨南大学 m6A RNA甲基化含量及其甲基化相关酶和结合蛋白在制备衰老检测试剂盒中的应用
CN114164216B (zh) * 2021-12-21 2023-08-25 北京航空航天大学 一种基因在促进骨形成中的应用

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10179148A (ja) 1996-12-26 1998-07-07 Kagaku Gijutsu Shinko Jigyodan ヒト小型肝細胞の取得方法と、この細胞の初代培養 および継代培養方法
WO2001048147A1 (en) 1999-12-28 2001-07-05 Iso Tis N.V. Cell culture medium containing growth factors and l-glutamine
WO2002000849A1 (en) 2000-06-26 2002-01-03 Renomedix Institute Inc. Cell fraction containing cells capable of differentiating into nervous system cells
JP2002518990A (ja) 1997-09-05 2002-07-02 サイトセラピューティックス，インコーポレイテッド ヒトｃｎｓ神経幹細胞の培養
JP2003052360A (ja) 2001-08-20 2003-02-25 Japan Science & Technology Corp 基底膜細胞外基質を用いた間葉系幹細胞の培養方法
WO2003038075A1 (en) 2001-10-30 2003-05-08 Renomedix Institute Inc. Method of inducing differentiation of mesodermal stem cells, es cells or immortalized cells into nervous system cells
JP2003235548A (ja) 2001-12-13 2003-08-26 Japan Science & Technology Corp ヒト細胞の培養用培地および培養方法
WO2005001732A1 (ja) 2003-06-27 2005-01-06 Renomedix Institute Inc. 治療用自己細胞配送支援システム及び治療用自己細胞配送支援金融システム、並びにそれらの方法
WO2005007176A1 (ja) 2003-06-27 2005-01-27 Renomedix Institute Inc. 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬
JP2005204539A (ja) 2004-01-21 2005-08-04 Mitsubishi Pharma Corp 造血幹細胞及び造血前駆細胞の増幅方法
JP2005218308A (ja) 2004-02-03 2005-08-18 National Institute Of Advanced Industrial & Technology 神経幹細胞増殖助剤及びこれを含んだ神経幹細胞用培地
JP2005531322A (ja) * 2002-07-02 2005-10-20 インスティトゥト シエンティフィコ イ テクノロジコ デ ナバッラ，ソシエダ アノニマ ヒト自己前駆幹細胞を培養する培地とその応用
JP2006034118A (ja) * 2004-07-23 2006-02-09 Kaneka Corp 間葉系幹細胞の効率的保存または調製方法
JP2006055106A (ja) 2004-08-23 2006-03-02 National Institute Of Advanced Industrial & Technology ヒト血清培地を用いるヒト骨髄由来間葉系幹細胞培養法
WO2006054448A1 (ja) * 2004-11-19 2006-05-26 Jms Co., Ltd. 細胞培養用ヒト血清
JP2006136281A (ja) 2004-11-15 2006-06-01 Olympus Corp 培地および間葉系幹細胞の培養方法
JP2007235436A (ja) 2006-02-28 2007-09-13 Sunx Ltd 電子回路及び光電センサ
JP2007236499A (ja) 2006-03-06 2007-09-20 Daiichi Shokai Co Ltd 遊技機
JP2007267211A (ja) 2006-03-29 2007-10-11 Ntt-It Corp コマーシャル検出方法およびコマーシャル検出装置並びにコマーシャル検出プログラムが記録された記録媒体
JP2007278049A (ja) 2006-04-07 2007-10-25 Voice Interface:Kk 凝固剤注入によるアスベスト封じ込めシステム
JP2007278083A (ja) 2006-04-03 2007-10-25 Nissan Motor Co Ltd 内燃機関の吸気制御装置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038139A (en) * 1976-07-16 1977-07-26 G. D. Searle & Co., Limited Cell culture medium
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5736396A (en) * 1995-01-24 1998-04-07 Case Western Reserve University Lineage-directed induction of human mesenchymal stem cell differentiation
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
JPWO2004076652A1 (ja) * 2003-02-25 2006-06-08 学校法人東海大学 椎間板再生用の幹細胞用培地及び幹細胞を用いた椎間板の再生
US20070178591A1 (en) * 2004-06-25 2007-08-02 Renomedix Institute, Inc Internally administered therapeutic agents for diseases in central and peripheral nervous system comprising mesenchymal cells as an active ingredient
US20060210544A1 (en) * 2003-06-27 2006-09-21 Renomedix Institute, Inc. Internally administered therapeutic agents for cranial nerve diseases comprising mesenchymal cells as an active ingredient
CN1590537A (zh) * 2003-09-02 2005-03-09 中国人民解放军第四军医大学口腔医学院 外胚间充质干细胞的分离和培养方法
CN1699557A (zh) 2005-05-26 2005-11-23 南开大学 一种骨髓间充质干细胞的分离及培养方法
US20070047270A1 (en) 2005-09-01 2007-03-01 Creative Technology Ltd. Load detector for an AC-AC power supply
JP2009506769A (ja) 2005-09-02 2009-02-19 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 間充織幹細胞誘導方法
PL3117828T3 (pl) * 2007-09-11 2020-05-18 Sapporo Medical University Sposób namnażania komórek i środek farmaceutyczny do naprawy i regeneracji tkanek

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10179148A (ja) 1996-12-26 1998-07-07 Kagaku Gijutsu Shinko Jigyodan ヒト小型肝細胞の取得方法と、この細胞の初代培養 および継代培養方法
JP2002518990A (ja) 1997-09-05 2002-07-02 サイトセラピューティックス，インコーポレイテッド ヒトｃｎｓ神経幹細胞の培養
WO2001048147A1 (en) 1999-12-28 2001-07-05 Iso Tis N.V. Cell culture medium containing growth factors and l-glutamine
WO2002000849A1 (en) 2000-06-26 2002-01-03 Renomedix Institute Inc. Cell fraction containing cells capable of differentiating into nervous system cells
JP2003052360A (ja) 2001-08-20 2003-02-25 Japan Science & Technology Corp 基底膜細胞外基質を用いた間葉系幹細胞の培養方法
WO2003038075A1 (en) 2001-10-30 2003-05-08 Renomedix Institute Inc. Method of inducing differentiation of mesodermal stem cells, es cells or immortalized cells into nervous system cells
JP2003235548A (ja) 2001-12-13 2003-08-26 Japan Science & Technology Corp ヒト細胞の培養用培地および培養方法
JP2005531322A (ja) * 2002-07-02 2005-10-20 インスティトゥト シエンティフィコ イ テクノロジコ デ ナバッラ，ソシエダ アノニマ ヒト自己前駆幹細胞を培養する培地とその応用
WO2005001732A1 (ja) 2003-06-27 2005-01-06 Renomedix Institute Inc. 治療用自己細胞配送支援システム及び治療用自己細胞配送支援金融システム、並びにそれらの方法
WO2005007176A1 (ja) 2003-06-27 2005-01-27 Renomedix Institute Inc. 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬
JP2005204539A (ja) 2004-01-21 2005-08-04 Mitsubishi Pharma Corp 造血幹細胞及び造血前駆細胞の増幅方法
JP2005218308A (ja) 2004-02-03 2005-08-18 National Institute Of Advanced Industrial & Technology 神経幹細胞増殖助剤及びこれを含んだ神経幹細胞用培地
JP2006034118A (ja) * 2004-07-23 2006-02-09 Kaneka Corp 間葉系幹細胞の効率的保存または調製方法
JP2006055106A (ja) 2004-08-23 2006-03-02 National Institute Of Advanced Industrial & Technology ヒト血清培地を用いるヒト骨髄由来間葉系幹細胞培養法
JP2006136281A (ja) 2004-11-15 2006-06-01 Olympus Corp 培地および間葉系幹細胞の培養方法
WO2006054448A1 (ja) * 2004-11-19 2006-05-26 Jms Co., Ltd. 細胞培養用ヒト血清
JP2007235436A (ja) 2006-02-28 2007-09-13 Sunx Ltd 電子回路及び光電センサ
JP2007236499A (ja) 2006-03-06 2007-09-20 Daiichi Shokai Co Ltd 遊技機
JP2007267211A (ja) 2006-03-29 2007-10-11 Ntt-It Corp コマーシャル検出方法およびコマーシャル検出装置並びにコマーシャル検出プログラムが記録された記録媒体
JP2007278083A (ja) 2006-04-03 2007-10-25 Nissan Motor Co Ltd 内燃機関の吸気制御装置
JP2007278049A (ja) 2006-04-07 2007-10-25 Voice Interface:Kk 凝固剤注入によるアスベスト封じ込めシステム

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Molecular Cloning: A Laboratory Manual", 2001, COLD SPRING HARBOR LABORATORY
F. TAKAKU: "Manual of Bone Marrow Transplantation", 1996, CHUGAI-IGAKUSHA, pages: 86
MORI, H. ET AL.: "Effects of heparin and its 6-O-and 2-O- desulfated derivatives with low anticoagulant activity on proliferation of human neural stem/progenitor cells", J BIOSCI.BIOENG., vol. 100, no. 1, July 2005 (2005-07-01), pages 54 - 61, XP005665534 *
See also references of EP2194121A4

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10563173B2 (en) 2010-08-03 2020-02-18 Nipro Corporation Autoserum-containing bone marrow cell culture system, autoserum-containing bone marrow cell culture method, and method for producing medicinal composition comprising autoserum-containing cultured bone marrow cells as active ingredient
JP5185470B2 (ja) * 2010-08-03 2013-04-17 北海道公立大学法人 札幌医科大学 自己血清添加骨髄細胞培養システム、自己血清添加骨髄細胞培養方法および自己血清添加培養骨髄細胞を有効成分とする医薬組成物の製造方法
US9683214B2 (en) 2010-08-03 2017-06-20 Sapporo Medical University Autoserum-containing bone marrow cell culture system, autoserum-containing bone marrow cell culture method, and method for producing medicinal composition comprising autoserum-containing cultured bone marrow cells as active ingredient
WO2012018040A1 (ja) 2010-08-03 2012-02-09 北海道公立大学法人札幌医科大学 自己血清添加骨髄細胞培養システム、自己血清添加骨髄細胞培養方法および自己血清添加培養骨髄細胞を有効成分とする医薬組成物の製造方法
JP2016506954A (ja) * 2013-02-06 2016-03-07 Ｎｃメディカルリサーチ株式会社 神経変性の治療のための細胞療法
US10874723B2 (en) 2013-02-06 2020-12-29 Nc Medical Research Inc. Cell therapy for the treatment of neurodegeneration
US10071144B2 (en) 2013-02-06 2018-09-11 Nc Medical Research Inc. Cell therapy for the treatment of neurodegeneration
US10149894B2 (en) 2013-02-06 2018-12-11 Nc Medical Research Inc. Cell therapy for the treatment of neurodegeneration
JP2017132744A (ja) * 2016-01-29 2017-08-03 学校法人東京女子医科大学 腎臓病進行抑制細胞シート組成物、その製造方法、及び、それを用いた腎臓病進行抑制方法
US11666601B2 (en) 2016-04-28 2023-06-06 Sapporo Medical University Synapse formation agent
KR20220166875A (ko) 2016-04-28 2022-12-19 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 시냅스 형성제
JP7076709B2 (ja) 2016-08-18 2022-05-30 北海道公立大学法人 札幌医科大学 間葉系幹細胞活性化剤
JPWO2018034023A1 (ja) * 2016-08-18 2019-06-13 北海道公立大学法人 札幌医科大学 寿命延長剤
JPWO2018034314A1 (ja) * 2016-08-18 2019-06-20 北海道公立大学法人 札幌医科大学 間葉系幹細胞活性化剤
WO2018034314A1 (ja) * 2016-08-18 2018-02-22 北海道公立大学法人札幌医科大学 間葉系幹細胞活性化剤
EP3501525A4 (en) * 2016-08-18 2020-04-08 Sapporo Medical University LIFETIME EXTENSION AGENT
WO2018034023A1 (ja) * 2016-08-18 2018-02-22 北海道公立大学法人札幌医科大学 寿命延長剤
JP7356097B2 (ja) 2016-08-18 2023-10-04 北海道公立大学法人 札幌医科大学 寿命延長剤
US11311579B2 (en) 2016-08-30 2022-04-26 Niigata University Cell preparation and method for producing cell preparation
KR20190042684A (ko) 2016-08-30 2019-04-24 고쿠리츠다이가쿠호진 니이가타 다이가쿠 세포 제제 및 세포 제제의 제조 방법
WO2018043596A1 (ja) 2016-08-30 2018-03-08 国立大学法人 新潟大学 細胞製剤および細胞製剤の製造方法
JP2017145259A (ja) * 2017-06-01 2017-08-24 Ｎｃメディカルリサーチ株式会社 神経変性の治療のための細胞療法
JP7306635B2 (ja) 2017-11-09 2023-07-11 北海道公立大学法人 札幌医科大学 組織再生用医薬及びその製造方法
JPWO2019093481A1 (ja) * 2017-11-09 2021-02-04 北海道公立大学法人 札幌医科大学 組織再生用医薬及びその製造方法
WO2019093481A1 (ja) 2017-11-09 2019-05-16 北海道公立大学法人札幌医科大学 組織再生用医薬及びその製造方法
JPWO2019208688A1 (ja) * 2018-04-25 2021-04-30 北海道公立大学法人 札幌医科大学 生体移植用細胞シート及びその製造方法
JP7353652B2 (ja) 2018-04-25 2023-10-02 北海道公立大学法人 札幌医科大学 生体移植用細胞シート及びその製造方法
US12090251B2 (en) 2018-04-25 2024-09-17 Sapporo Medical University Cell sheet for transplantation into living body and method for producing same
WO2019208688A1 (ja) * 2018-04-25 2019-10-31 北海道公立大学法人札幌医科大学 生体移植用細胞シート及びその製造方法
KR20210126025A (ko) 2019-02-07 2021-10-19 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 스텐트 내 재협착의 예방을 위한 의약 조성물
WO2020162580A1 (ja) 2019-02-07 2020-08-13 北海道公立大学法人 札幌医科大学 ステント内再狭窄の予防のための医薬組成物
JPWO2020184729A1 (ja) * 2019-03-14 2020-09-17
WO2020184729A1 (ja) 2019-03-14 2020-09-17 北海道公立大学法人札幌医科大学 筋萎縮性側索硬化症の治療用医薬組成物
JP7541699B2 (ja) 2019-03-14 2024-08-29 北海道公立大学法人 札幌医科大学 筋萎縮性側索硬化症の治療用医薬組成物
KR20210138655A (ko) 2019-03-14 2021-11-19 훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 근위축성 측삭 경화증의 치료용 의약 조성물
AU2020236160B2 (en) * 2019-03-14 2025-07-24 Nipro Corporation Pharmaceutical composition for treating amyotrophic lateral sclerosis
JPWO2021132662A1 (ja) * 2019-12-27 2021-07-01
WO2021132662A1 (ja) * 2019-12-27 2021-07-01 北海道公立大学法人 札幌医科大学 哺乳動物細胞を培養するための血清の製造方法
JP7663202B2 (ja) 2019-12-27 2025-04-16 北海道公立大学法人 札幌医科大学 哺乳動物細胞を培養するための血清の製造方法
WO2022049977A1 (ja) * 2020-09-03 2022-03-10 株式会社ツーセル 中枢神経疾患の治療用組成物、中枢神経疾患の治療用組成物の製造方法および中枢神経疾患の治療用製剤の製造方法
AU2021337035B2 (en) * 2020-09-03 2025-04-17 Two Cells Co., Ltd. Composition for treating central nervous system diseases, method for producing composition for treating central nervous system diseases, and method for producing therapeutic formulation for central nervous system diseases
JP2023035950A (ja) * 2021-08-31 2023-03-13 約書亞健康事業股▲ふん▼有限公司 ヘルニア嚢から間葉系幹細胞を単離精製する方法、及び組織修復するためのヘルニア嚢由来の間葉系幹細胞の使用
JP7441447B2 (ja) 2021-08-31 2024-03-01 約書亞健康事業股▲ふん▼有限公司 ヘルニア嚢から間葉系幹細胞を単離精製する方法、及び組織修復するためのヘルニア嚢由来の間葉系幹細胞の使用

Also Published As

Publication number Publication date
CN101802174A (zh) 2010-08-11
CA2699236C (en) 2017-02-28
US10328102B2 (en) 2019-06-25
US20190255118A1 (en) 2019-08-22
DK3117828T3 (da) 2020-03-09
EP2194121B1 (en) 2016-10-26
US9700582B2 (en) 2017-07-11
KR20100072240A (ko) 2010-06-30
JPWO2009034708A1 (ja) 2010-12-24
EP3117828B1 (en) 2020-02-12
US11426432B2 (en) 2022-08-30
KR20170116219A (ko) 2017-10-18
PL3117828T3 (pl) 2020-05-18
US20170266234A1 (en) 2017-09-21
EP2194121A1 (en) 2010-06-09
DK2194121T3 (en) 2016-12-12
ES2611021T3 (es) 2017-05-04
AU2008298816B2 (en) 2013-09-26
JP4936341B2 (ja) 2012-05-23
CN101802174B (zh) 2013-06-05
CA2699236A1 (en) 2009-03-19
EP3117828A1 (en) 2017-01-18
PL2194121T3 (pl) 2017-02-28
EP2194121A4 (en) 2012-03-07
KR102087366B1 (ko) 2020-03-10
KR101614823B1 (ko) 2016-04-22
ES2776408T3 (es) 2020-07-30
KR20160005140A (ko) 2016-01-13
PT3117828T (pt) 2020-03-17
PT2194121T (pt) 2016-12-05
AU2008298816A1 (en) 2009-03-19
US20100254953A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
WO2009034708A1 (ja) 細胞増殖方法ならびに組織の修復および再生のための医薬
KR102124837B1 (ko) 기질 줄기 세포
WO2007035843A3 (en) Methods and compositions for organ and tissue functionality
EP3190180A3 (en) A method for identifying, expanding, and removing adult stem cells and cancer stem cells
AU2012274478A8 (en) Method for amplifying NK cells
BR0210599A (pt) Uso de monóxido de carbono, método para manutenção de uma célula animal in vitro, artigo de manufatura, bem como meio celular estéril
WO2008108412A1 (ja) 血清調製方法及び血清調製装置
WO2005065419A3 (en) Method of culturing cells
WO2008055224A3 (en) Lithium stimulation of cord blood stem cell proliferation and growth factor production
WO2008009711A3 (en) Use of soluble cd160 to suppress immunity
ATE535256T1 (de) Verfahren und zusammensetzung zur entfernung spezifischer zellpopulationen aus blutgeweben
WO2009035612A3 (en) Multilineage-inducible cells and uses thereof
CA2450789A1 (en) Schwann cells originating in myeloid interstitial cells
JP6189747B2 (ja) ヒアルロン酸産生能を有する細胞シート及びその製造方法
WO2011037416A3 (ko) 세포이식술을 위한 혼합세포복합체인 세포스페로이드의 제조방법 및 이의 이용방법
ITUB20159750A1 (it) Metodo per la promozione ed il miglioramento delle proprieta? del tessuto adiposo, tessuto e cellule ottenute tramite detto metodo
MX336067B (es) Celula madre para uso terapeutico, la cual se deriva de monocito humano y metodo para inducir la misma.
ATE438421T1 (de) Dreidimensionale matrix basiert auf hyaluronsäure-derivaten
Farrokhi et al. The immunomodulatory potential of murine adipose-derived mesenchymal stem cells is enhanced following culture on chitosan film
CN103087979A (zh) 用于富集、提纯干细胞的方法、试剂盒及其应用方法
EP1815856A3 (en) A cancer vaccine
WO2013049856A8 (en) Renal stem cells isolated from kidney
Human 2.2 Cell Culture
WO2009094340A3 (en) Omentum and use thereof
WO2009019758A1 (ja) 腎臓幹／前駆細胞の分離方法及び腎臓幹／前駆細胞、並びに腎疾患治療剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880106584.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08830989

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2699236

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008298816

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2008830989

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008830989

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1899/CHENP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107007607

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009532060

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2008298816

Country of ref document: AU

Date of ref document: 20080910

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12677610

Country of ref document: US